Applications Are Open: 2026 Power Player Awards
Nominate yourself (or someone who deserves it).
Novo Nordisk's CEO says the company’s blockbuster obesity drugs could ultimately pull it into increasingly buzzy areas of healthcare, from longevity research to aesthetic medicine.
Hims & Hers and Novo Nordisk are partners again, just weeks after Novo sued the telehealth giant for selling compounded GLP-1s.
Hims & Hers is planting its flag in new overseas markets; on U.S. soil, it's navigating a GLP-1s fight against Big Pharma's branded blockbusters.
Hims & Hers' Dr. Craig Primack explains why personalized care, not just GLP-1s, is the key to lasting weight loss success.
With a pharma giant in its corner, WeightWatchers is mounting a comeback, relying on FDA-approved GLP-1 medications.
Novo Nordisk ends its Wegovy deal with Hims & Hers, citing safety concerns as the telehealth firm pushes back.
Hims & Hers and Novo Nordisk are teaming to expand affordable access to weight loss treatments, launching a bundled Wegovy offering.
Sign Up to Our Newsletter
